Results 11 to 20 of about 10,402 (207)
Pegylated liposomal doxorubicin in ovarian cancer
Therapeutics and Clinical Risk Management, 2009 Robert Strother1,2, Daniela Matei1–51Department of Medicine, 2Indiana University Melvin and Bren Simon Cancer Center, 3Department of Obstetrics and Gynecology, 4Department of Biochemistry and Molecular Biology, 5VA Roudebush Hospital Indiana ...
Robert Strother, Daniela Matei
doaj +7 more sources
Cancer Biology & Medicine, 2009 OBJECTIVE To evaluate the efficacy and adverse effects of gemcitabine versus pegylated liposomal doxorubicin in patients with progressive or recurrent ovarian cancer.
Xia LIU, Li MA, Jinhui TIAN
doaj +2 more sources
Haematologica, 2011 Background The prognosis of acute lymphoblastic leukemia in the elderly is poor. The GRAALL-SA1 phase II, randomized trial compared the efficacy and toxicity of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in patients 55 years ...
Mathilde Hunault-Berger +19 more
doaj +2 more sources
PLoS ONE, 2014 Brain cancer is a devastating disease affecting many people worldwide. Effective treatment with chemotherapeutics is limited due to the presence of the blood-brain barrier (BBB) that tightly regulates the diffusion of endogenous molecules but also ...
Pieter J Gaillard +10 more
doaj +2 more sources
Exploring the Use of Pegylated Liposomal Doxorubicin (Caelyx®) as Pressurized Intraperitoneal Aerosol Chemotherapy [PDF]
Frontiers in Pharmacology, 2019 Background: Peritoneal carcinomatosis is a common metastatic pattern in ovarian, gastric, colorectal, and appendiceal cancer; systemic chemotherapy is the current standard of care for peritoneal metastatic disease; however, in a subset of patients its ...
Manuela Robella +7 more
doaj +2 more sources
Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice [PDF]
BMC Research Notes, 2018 Objective We wanted to determine the impact of different doses of a pegylated and liposomal formulation of the cardiotoxic drug doxorubicin on cardiac function, fibrosis and survival in mice. The drug causes myocardial damage by producing reactive oxygen
Christoffer Stark +3 more
doaj +3 more sources
Prolonged use of pegylated liposomal doxorubicin in gynecologic malignancies
Gynecologic Oncology Reports, 2019 Pegylated liposomal doxorubicin (PLD) is a palliative treatment option for patients with recurrent gynecologic malignancies. It has an appealing toxicity profile and responses can be prolonged.
S. Yost, J.L. Konal, A.V. Hoekstra
doaj +3 more sources
Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma
Biologics: Targets & Therapy, 2009 Francesca Cainelli1, Alfredo Vallone21Department of Internal Medicine, School of Medicine, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana; 2Infectious Diseases Unit, Annunziata Hospital, Cosenza, ItalyAbstract: Kaposi’s ...
Francesca Cainelli, Alfredo Vallone
doaj +1 more source
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer [PDF]
Journal of Ovarian Research, 2021 Objective To evaluate the efficacy and safety of PLD in treating of in patients who experience epithelial ovarian, fallopian tubal, and peritoneal cancer progression within 12 months after the first-line platinum-based therapy.
Zhen Yuan +19 more
doaj +3 more sources
Pegylated liposomal doxorubicin in the management of ovarian cancer
Therapeutics and Clinical Risk Management, 2010 Gabriella Ferrandina1,2, Giacomo Corrado1, Angelo Licameli1, Domenica Lorusso2, Gilda Fuoco1, Salvatore Pisconti3, Giovanni Scambia2 1Gynecologic Oncology Unit, Department of Oncology, Catholic University of Campobasso, Campobasso, Italy; 2Gynecologic ...
Gabriella Ferrandina +3 more
doaj +6 more sources